$BRKR
BRUKER CORP

2023 Q4 Form 10-Q Financial Statement

#000095017023062192 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q3
Revenue $854.5M $742.8M $638.9M
YoY Change 20.62% 16.26% 4.93%
Cost Of Revenue $424.2M $360.0M $303.6M
YoY Change 23.75% 18.58% 1.13%
Gross Profit $430.3M $382.8M $335.3M
YoY Change 17.7% 14.17% 8.62%
Gross Profit Margin 50.36% 51.53% 52.48%
Selling, General & Admin $211.3M $177.6M $144.8M
YoY Change 26.45% 22.65% 2.4%
% of Gross Profit 49.11% 46.39% 43.19%
Research & Development $83.40M $71.30M $56.20M
YoY Change 31.34% 26.87% 7.87%
% of Gross Profit 19.38% 18.63% 16.76%
Depreciation & Amortization $37.30M $26.60M $21.00M
YoY Change 52.24% 26.67% -5.41%
% of Gross Profit 8.67% 6.95% 6.26%
Operating Expenses $326.8M $258.3M $204.0M
YoY Change 42.77% 26.62% 5.43%
Operating Profit $103.5M $124.5M $131.3M
YoY Change -24.29% -5.18% 13.98%
Interest Expense -$6.700M $3.900M -$2.000M
YoY Change -33.0% -295.0% -54.55%
% of Operating Profit -6.47% 3.13% -1.52%
Other Income/Expense, Net $0.00 -$5.300M -$2.000M
YoY Change 165.0% -54.55%
Pretax Income $240.9M $119.2M $129.3M
YoY Change 99.09% -7.81% 18.84%
Income Tax $37.10M $30.80M $41.20M
% Of Pretax Income 15.4% 25.84% 31.86%
Net Earnings $205.5M $88.10M $88.10M
YoY Change 110.99% 0.0% 1.15%
Net Earnings / Revenue 24.05% 11.86% 13.79%
Basic Earnings Per Share $0.60 $0.60
Diluted Earnings Per Share $1.41 $0.60 $0.59
COMMON SHARES
Basic Shares Outstanding 138.4M 146.9M 148.1M
Diluted Shares Outstanding 147.3 148.6

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $488.3M $363.6M $626.2M
YoY Change -24.35% -41.94% -6.51%
Cash & Equivalents $488.3M $363.6M $626.2M
Short-Term Investments $0.00
Other Short-Term Assets $216.4M $264.4M $239.6M
YoY Change 11.83% 10.35% 11.65%
Inventory $968.3M $916.0M $749.5M
Prepaid Expenses $26.70M $26.70M
Receivables $492.0M $485.4M $421.3M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $2.165B $2.029B $2.037B
YoY Change 2.45% -0.35% 2.38%
LONG-TERM ASSETS
Property, Plant & Equipment $599.7M $527.0M $421.5M
YoY Change 23.14% 25.03% 8.24%
Goodwill $582.6M $561.1M $381.5M
YoY Change 27.32% 47.08%
Intangibles $330.5M $291.9M $214.0M
YoY Change 22.0% 36.4%
Long-Term Investments
YoY Change
Other Assets $184.0M $410.2M $283.3M
YoY Change 18.63% 44.79% 36.79%
Total Long-Term Assets $2.074B $1.790B $1.300B
YoY Change 38.38% 37.68% 14.22%
TOTAL ASSETS
Total Short-Term Assets $2.165B $2.029B $2.037B
Total Long-Term Assets $2.074B $1.790B $1.300B
Total Assets $4.239B $3.820B $3.337B
YoY Change 17.36% 14.47% 6.69%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $202.7M $181.5M $157.7M
YoY Change 13.62% 15.09% 11.76%
Accrued Expenses
YoY Change
Deferred Revenue $400.0M $175.5M
YoY Change 83.49%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $121.2M $121.0M $17.00M
YoY Change 548.13% 611.76% -84.47%
Total Short-Term Liabilities $1.191B $1.072B $864.6M
YoY Change 30.26% 24.02% -6.14%
LONG-TERM LIABILITIES
Long-Term Debt $1.160B $1.099B $1.137B
YoY Change -3.35% -3.36% 58.44%
Other Long-Term Liabilities $474.2M $404.5M $381.8M
YoY Change 185.32% 5.95% -4.33%
Total Long-Term Liabilities $1.635B $1.503B $1.519B
YoY Change 19.59% -1.02% 36.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.191B $1.072B $864.6M
Total Long-Term Liabilities $1.635B $1.503B $1.519B
Total Liabilities $2.844B $2.575B $2.383B
YoY Change 24.69% 8.06% 16.13%
SHAREHOLDERS EQUITY
Retained Earnings $2.324B
YoY Change 20.65%
Common Stock $282.9M
YoY Change 10.38%
Preferred Stock
YoY Change
Treasury Stock (at cost) $1.237B $1.187B $1.059B
YoY Change 14.03% 12.12%
Treasury Stock Shares $27.93M
Shareholders Equity $1.395B $1.209B $937.0M
YoY Change
Total Liabilities & Shareholders Equity $4.239B $3.820B $3.337B
YoY Change 17.36% 14.47% 6.69%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q3
OPERATING ACTIVITIES
Net Income $205.5M $88.10M $88.10M
YoY Change 110.99% 0.0% 1.15%
Depreciation, Depletion And Amortization $37.30M $26.60M $21.00M
YoY Change 52.24% 26.67% -5.41%
Cash From Operating Activities $205.5M $44.10M $69.50M
YoY Change 19.83% -36.55% 190.79%
INVESTING ACTIVITIES
Capital Expenditures $31.50M $26.90M -$57.70M
YoY Change -8.96% -146.62% 253.99%
Acquisitions
YoY Change
Other Investing Activities -$5.200M -$128.1M $100.0K
YoY Change -95.47% -128200.0% -100.31%
Cash From Investing Activities -$36.70M -$155.0M -$57.60M
YoY Change -75.42% 169.1% 19.01%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -59.90M -92.50M -82.00M
YoY Change 65.93% 12.8% 3053.85%
NET CHANGE
Cash From Operating Activities 205.5M 44.10M 69.50M
Cash From Investing Activities -36.70M -155.0M -57.60M
Cash From Financing Activities -59.90M -92.50M -82.00M
Net Change In Cash 108.9M -203.4M -70.10M
YoY Change -883.45% 190.16% 158.67%
FREE CASH FLOW
Cash From Operating Activities $205.5M $44.10M $69.50M
Capital Expenditures $31.50M $26.90M -$57.70M
Free Cash Flow $174.0M $17.20M $127.2M
YoY Change 27.1% -86.48% 216.42%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001109354
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-30833
dei Entity Registrant Name
EntityRegistrantName
BRUKER CORPORATION
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3110160
dei Entity Address Address Line1
EntityAddressAddressLine1
40 Manning Road
dei Entity Address City Or Town
EntityAddressCityOrTown
Billerica
dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01821
dei City Area Code
CityAreaCode
978
dei Local Phone Number
LocalPhoneNumber
663-3660
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
BRKR
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
138411212
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
363600000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
645500000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
485400000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
472700000
CY2023Q3 us-gaap Inventory Net
InventoryNet
916000000
CY2022Q4 us-gaap Inventory Net
InventoryNet
800100000
CY2023Q3 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
0
CY2022Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
1400000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
264400000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
193500000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
2029400000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
2113200000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
527000000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
487000000
CY2023Q3 us-gaap Goodwill
Goodwill
561100000
CY2022Q4 us-gaap Goodwill
Goodwill
457600000
CY2023Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
291900000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
270900000
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
410200000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
283100000
CY2023Q3 us-gaap Assets
Assets
3819600000
CY2022Q4 us-gaap Assets
Assets
3611800000
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121000000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
18700000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
181500000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
178400000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
381200000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
370200000
CY2023Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
388600000
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
347000000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
1072300000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
914300000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1098600000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1200500000
CY2023Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
404500000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
365200000
CY2023Q3 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
17100000
CY2022Q4 us-gaap Redeemable Noncontrolling Interest Equity Carrying Amount
RedeemableNoncontrollingInterestEquityCarryingAmount
6100000
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
260000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175826534
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
175389586
us-gaap Operating Expenses
OperatingExpenses
749600000
us-gaap Operating Expenses
OperatingExpenses
638100000
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
145901313
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
147023144
CY2023Q3 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2022Q4 us-gaap Common Stock Value Outstanding
CommonStockValueOutstanding
1700000
CY2023Q3 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
29925221
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
28366442
CY2023Q3 us-gaap Treasury Stock Value
TreasuryStockValue
1186900000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
1085000000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-5200000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
14800000
CY2023Q3 brkr Other Shareholders Equity
OtherShareholdersEquity
2399200000
CY2022Q4 brkr Other Shareholders Equity
OtherShareholdersEquity
2182300000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
1208800000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
1113800000
CY2023Q3 us-gaap Minority Interest
MinorityInterest
18300000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
11900000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1227100000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1125700000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3819600000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3611800000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
638900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1822300000
CY2023Q3 us-gaap Cost Of Revenue
CostOfRevenue
360000000
CY2022Q3 us-gaap Cost Of Revenue
CostOfRevenue
303600000
us-gaap Cost Of Revenue
CostOfRevenue
1027000000
us-gaap Cost Of Revenue
CostOfRevenue
882500000
CY2023Q3 us-gaap Gross Profit
GrossProfit
382800000
CY2022Q3 us-gaap Gross Profit
GrossProfit
335300000
us-gaap Gross Profit
GrossProfit
1083000000
us-gaap Gross Profit
GrossProfit
939800000
CY2023Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
177600000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
144800000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
518200000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
442700000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
71300000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
56200000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
211300000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
172400000
CY2023Q3 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
9400000
CY2022Q3 us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
3000000
us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
20100000
us-gaap Other Nonrecurring Expense
OtherNonrecurringExpense
23000000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
258300000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
204000000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
124500000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
131300000
us-gaap Operating Income Loss
OperatingIncomeLoss
333400000
us-gaap Operating Income Loss
OperatingIncomeLoss
301700000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5300000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30100000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8800000
CY2023Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
119200000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
129300000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
303300000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
292900000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30800000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41200000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93000000
CY2023Q3 brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
300000
CY2022Q3 brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
300000
brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
1200000
brkr Equity In Income Of Unconsolidated Investees Net Of Tax
EquityInIncomeOfUnconsolidatedInvesteesNetOfTax
300000
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88700000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
88400000
us-gaap Profit Loss
ProfitLoss
223900000
us-gaap Profit Loss
ProfitLoss
200200000
CY2023Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
600000
CY2022Q3 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
300000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
2200000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
1000000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
88100000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
88100000
us-gaap Net Income Loss
NetIncomeLoss
221700000
us-gaap Net Income Loss
NetIncomeLoss
199200000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.6
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.51
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.34
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.6
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.33
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.6
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147.8
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.7
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
149.1
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.3
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148.6
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.5
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149.9
CY2023Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
58000000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
44600000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
203500000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
113700000
CY2023Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
300000
CY2022Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
-300000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
2900000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
-500000
CY2023Q3 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-800000
CY2022Q3 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-600000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-1100000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-1300000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58500000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
45500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
201700000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
115500000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1125700000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
700000
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-100000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2023Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
22300000
CY2023Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
5300000
CY2023Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
77500000
CY2023Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
15100000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1198800000
CY2023Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
500000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4100000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1800000
CY2023Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q2 us-gaap Payments To Minority Shareholders
PaymentsToMinorityShareholders
300000
CY2023Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
58200000
CY2023Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-5000000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1250700000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5200000
CY2023Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3200000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4600000
CY2023Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
200000
CY2023Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
80300000
CY2023Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2023Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2023Q3 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1500000
CY2023Q3 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
89100000
CY2023Q3 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-30300000
CY2023Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1227100000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1084600000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3100000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3800000
CY2022Q1 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
105600000
CY2022Q1 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2022Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7500000
CY2022Q1 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
62100000
CY2022Q1 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-9200000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
1031300000
CY2022Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
200000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3800000
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
60300000
CY2022Q2 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2022Q2 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7500000
CY2022Q2 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
49900000
CY2022Q2 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-33000000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
984400000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
600000
CY2022Q3 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-3100000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3900000
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
72400000
CY2022Q3 us-gaap Common Stock Dividends Per Share Cash Paid
CommonStockDividendsPerShareCashPaid
0.05
CY2022Q3 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
7400000
CY2022Q3 brkr Net Income Loss Including Portion Attributable To Redeemable Noncontrolling Interest
NetIncomeLossIncludingPortionAttributableToRedeemableNoncontrollingInterest
88600000
CY2022Q3 us-gaap Noncontrolling Interest Increase From Business Combination
NoncontrollingInterestIncreaseFromBusinessCombination
3200000
CY2022Q3 brkr Other Comprehensive Income Loss Net Of Tax Excluding Redeemable Noncontrolling Interest
OtherComprehensiveIncomeLossNetOfTaxExcludingRedeemableNoncontrollingInterest
-43400000
CY2022Q3 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
948000000
us-gaap Profit Loss
ProfitLoss
223900000
us-gaap Profit Loss
ProfitLoss
200200000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
77600000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64300000
us-gaap Share Based Compensation
ShareBasedCompensation
17800000
us-gaap Share Based Compensation
ShareBasedCompensation
23000000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
12800000
us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
-25700000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
19500000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
0
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
6800000
us-gaap Equity Method Investment Realized Gain Loss On Disposal
EquityMethodInvestmentRealizedGainLossOnDisposal
0
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
9400000
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
0
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-18300000
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
-11800000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
12400000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
39700000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
147300000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
139100000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
11100000
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
300000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-13500000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
10600000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
6500000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
10500000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
53500000
us-gaap Increase Decrease In Other Operating Capital Net
IncreaseDecreaseInOtherOperatingCapitalNet
13300000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
144600000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
102900000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
75400000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
94600000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
100000000
brkr Proceeds From Disposal Of Minority Investment
ProceedsFromDisposalOfMinorityInvestment
-11800000
brkr Proceeds From Disposal Of Minority Investment
ProceedsFromDisposalOfMinorityInvestment
0
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
19300000
us-gaap Payments For Proceeds From Investments
PaymentsForProceedsFromInvestments
40800000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
222300000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
85500000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
10900000
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13800000
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-5100000
us-gaap Payments For Proceeds From Hedge Investing Activities
PaymentsForProceedsFromHedgeInvestingActivities
-4800000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-289200000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-102300000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
3200000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-7000000
us-gaap Proceeds From Repayments Of Other Debt
ProceedsFromRepaymentsOfOtherDebt
-1200000
brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
0
brkr Repayment Of Two Thousand Twelve Notes Purchase Agreement
RepaymentOfTwoThousandTwelveNotesPurchaseAgreement
-105000000
brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-11300000
brkr Repayment Of Two Thousand Nineteen Notes Purchase Agreement
RepaymentOfTwoThousandNineteenNotesPurchaseAgreement
-2300000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4800000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
800000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
2700000
us-gaap Payment For Contingent Consideration Liability Financing Activities
PaymentForContingentConsiderationLiabilityFinancingActivities
1700000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22100000
us-gaap Payments Of Dividends Common Stock
PaymentsOfDividendsCommonStock
22400000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
101900000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
236800000
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
3500000
us-gaap Proceeds From Payments To Minority Shareholders
ProceedsFromPaymentsToMinorityShareholders
-10600000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-133500000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-379200000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-3700000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-63800000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-281800000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-442400000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
648700000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1071700000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
366900000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
629300000
CY2022Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3200000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3500000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3300000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
3100000
us-gaap Nature Of Operations
NatureOfOperations
<div style="text-indent:0;display:flex;margin-top:10pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:3.333%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;text-indent:0;display:inline-flex;font-size:10pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Description of Business</span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Bruker Corporation, together with its consolidated subsidiaries (Bruker or the Company), develops, manufactures and distributes high-performance scientific instruments and analytical and diagnostic solutions that enable its customers to explore life and materials at microscopic, molecular and cellular levels. Many of the Company’s products are used to detect, measure and visualize structural characteristics of chemical, biological and industrial material samples. The Company’s products address the rapidly evolving needs of a diverse array of customers in life science research, pharmaceuticals, biotechnology, applied markets, cell biology, clinical research, microbiology, in-vitro diagnostics, nanotechnology and materials science research.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has </span><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">four</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> reportable segments, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI NANO and Bruker Energy &amp; Supercon Technologies (BEST).</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI BioSpin Segment designs, manufactures and distributes enabling life science tools based on magnetic resonance technology. BSI BioSpin Segment’s revenues are generated by academic and government research customers, pharmaceutical and biotechnology companies and nonprofit laboratories, as well as chemical, food and beverage, clinical and other industrial companies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI CALID (Chemicals, Applied Markets, Life Science, In Vitro Diagnostics, Detection) Segment designs, manufactures and distributes life science mass spectrometry and ion mobility spectrometry solutions, analytical and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies and radiological/nuclear detectors for Chemical, Biological, Radiological, Nuclear and Explosive (CBRNE) detection. Customers of the BSI CALID Segment include academic institutions and medical schools; pharmaceutical, biotechnology and diagnostics companies; contract research organizations; nonprofit and for-profit forensics laboratories; agriculture, food and beverage safety laboratories; environmental and clinical microbiology laboratories; hospitals and government departments and agencies.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BSI NANO Segment designs, manufactures and distributes advanced X-ray instruments; atomic force microscopy instrumentation; advanced fluorescence optical microscopy instruments; analytical tools for electron microscopes and X-ray metrology; defect-detection equipment for semiconductor process control; handheld, portable and mobile X-ray fluorescence spectrometry instruments; spark optical emission spectroscopy systems; chip cytometry products and services for targeted spatial proteomics, multi-omic services; and products and services for spatial genomics research. Customers of the BSI NANO Segment include academic institutions, governmental customers, nanotechnology companies, semiconductor companies, raw material manufacturers, industrial companies, biotechnology and pharmaceutical companies and other businesses involved in materials research and life science research analysis.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BEST Segment develops and manufactures superconducting and non-superconducting materials and devices for use in renewable energy, energy infrastructure, healthcare and “big science” research. The segment focuses on metallic low temperature superconductors for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The unaudited condensed consolidated financial statements represent the consolidated accounts of the Company. All intercompany accounts and transactions have been eliminated in consolidation. The unaudited condensed consolidated financial statements as of September 30, 2023 and December 31, 2022, and for the three and nine months ended September 30, 2023 and 2022, have been prepared in accordance with accounting principles generally accepted in the United States of America (GAAP) for interim financial information and pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Accordingly, the financial information presented herein does not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments, consisting only of normal recurring adjustments, considered necessary for a fair statement have been included. The results for interim periods are not necessarily indicative of the results expected for any other interim period or the full year.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">At September 30, 2023, the Company’s significant accounting policies, which are detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, have not changed.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Risks and Uncertainties</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company is subject to risks common to its industry including, but not limited to, global economic conditions, such as increasing inflation, uncertainties caused by recent banking industry volatility, rapid technological change, government and academic funding levels, geopolitical uncertainties, changes in commodity prices, spending patterns of its customers, protection of its intellectual property, availability of key raw materials and components and other supply chain challenges, compliance with existing and future regulation by government agencies and fluctuations in foreign currency exchange rates and interest rates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company has experienced supply chain interruptions as a result of general global economic conditions, including inflation and the threat of a potential recession, a tighter labor market and other factors including natural events and disasters. Various factors, including increased demand for certain components and production delays, are contributing to shortages of certain components used in the Company’s products and increased difficulties in the Company’s ability to obtain a consistent supply of materials at stable pricing levels. Supply shortages and longer lead times for components used in the Company’s products, including limited source components, has resulted and may continue to cause disruptions to the Company’s production activities, which has had and may continue to have an adverse effect on the Company’s financial condition or result of operations. These factors have impacted and may continue to impact the timing of the Company’s revenue, and have also resulted, and may in the future result in a delay of revenue, and an increase in manufacturing costs, all of which have adversely impacted and may continue to adversely impact the Company’s operating results.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additionally, world events, such as the Russia-Ukraine conflict and related economic sanctions, the conflict in Israel, Palestine and surrounding areas, the possible expansion of such conflicts and potential geopolitical consequences, the ongoing tensions between the United States and China, tariff and trade policy changes, and increasing potential of conflict involving countries in Asia that are significant to the Company's supply chain operations, such as Taiwan and China, have resulted in increasing global instability and have created uncertainty for global commerce. As a result of the adverse economic impacts resulting from the Russia-Ukraine conflict, such as increased prices for and a reduced supply of key metals used in our products, the Company has ceased its Russian operations. Sustained or worsening global economic conditions and increasing inflation and geopolitical tensions have increased the Company's cost of doing business, impacted the Company's supply chain operations, caused some of the Company's customers to reduce or delay spending and further intensified pricing pressures. Combined with increased inflation, potential energy shortages in Europe where we have significant operations, and overall higher energy and transportation costs, these factors have affected and may continue to affect the Company's financial condition and results of operations.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements requires the Company to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. On an ongoing basis the Company evaluates estimates, judgments and methodologies. Changes in estimates are recorded in the period in which they become known. The Company bases its estimates on historical experience and on various other assumptions that it believes are reasonable, the results of which form the basis for making judgments about the carrying values of assets, liabilities and equity and the amount of revenues and expenses. The full extent to which the global supply chain interruptions, higher energy costs and shortages, the global economy, including inflation and the threat of recession, and geopolitical instability will directly or indirectly impact future business, results of operations and financial condition, including sales, expenses, reserves and allowances, manufacturing, research and development costs and employee cost related amounts, will depend on future developments that are highly uncertain, including as a result of new developments concerning global supply chain and various global conflicts. The Company has made estimates of the impact of these disruptions within the financial statements and there may be changes to those estimates in future periods. Actual results may differ from management’s estimates if these results differ from historical experience.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Deferred revenue previously included in other current liabilities on the consolidated balance sheets is currently presented together with customer advances. The change in the prior period was made to conform to the current period presentation.</span></p>
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
4
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
638900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1822300000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
638900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1822300000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
742800000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
638900000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2110000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1822300000
CY2023Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2189400000
CY2023Q3 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
90000000
CY2022Q4 us-gaap Contract With Customer Asset Net
ContractWithCustomerAssetNet
61300000
CY2023Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
475400000
CY2022Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
471700000
CY2022 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
304900000
CY2023Q3 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
88500000
CY2022Q4 us-gaap Unbilled Contracts Receivable
UnbilledContractsReceivable
60800000
CY2023Q3 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
82300000
CY2022Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
61800000
CY2023Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
26700000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
24300000
CY2023Q3 us-gaap Deposits Assets Current
DepositsAssetsCurrent
30.5
CY2022Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
19
CY2023Q3 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
36400000
CY2022Q4 us-gaap Other Assets Miscellaneous Current
OtherAssetsMiscellaneousCurrent
27600000
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
264400000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
193500000
us-gaap Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
43800000
brkr Payments To Acquire Businesses Cash Acquired
PaymentsToAcquireBusinessesCashAcquired
23500000
brkr Payments To Acquire Businesse Goodwill
PaymentsToAcquireBusinesseGoodwill
30100000
CY2023Q3 us-gaap Gain Loss On Disposition Of Other Financial Assets
GainLossOnDispositionOfOtherFinancialAssets
0
CY2022Q3 us-gaap Gain Loss On Disposition Of Other Financial Assets
GainLossOnDispositionOfOtherFinancialAssets
0
us-gaap Gain Loss On Disposition Of Other Financial Assets
GainLossOnDispositionOfOtherFinancialAssets
6800000
us-gaap Gain Loss On Disposition Of Other Financial Assets
GainLossOnDispositionOfOtherFinancialAssets
1700000
CY2023Q3 us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
18300000
us-gaap Other Asset Impairment Charges
OtherAssetImpairmentCharges
0
CY2023Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
331800000
CY2023Q3 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
339600000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
300900000
CY2023Q3 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
315600000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
278700000
CY2023Q3 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
160600000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
128200000
CY2023Q3 us-gaap Other Inventory Demo
OtherInventoryDemo
100200000
CY2022Q4 us-gaap Other Inventory Demo
OtherInventoryDemo
92300000
CY2023Q3 us-gaap Inventory Net
InventoryNet
916000000
CY2022Q4 us-gaap Inventory Net
InventoryNet
800100000
CY2023Q3 us-gaap Other Inventory In Transit
OtherInventoryInTransit
47500000
CY2022Q4 us-gaap Other Inventory In Transit
OtherInventoryInTransit
41100000
CY2022Q4 us-gaap Goodwill
Goodwill
457600000
us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
105000000
us-gaap Goodwill Foreign Currency Translation Gain Loss
GoodwillForeignCurrencyTranslationGainLoss
-1500000
CY2023Q3 us-gaap Goodwill
Goodwill
561100000
CY2023Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
623700000
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.34
CY2023Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
291900000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
570300000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
299400000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
270900000
CY2023Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
11500000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
8900000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
33400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
27500000
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
us-gaap Goodwill And Intangible Asset Impairment
GoodwillAndIntangibleAssetImpairment
0
CY2023Q3 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1400000
CY2022Q4 us-gaap Deferred Finance Costs Net
DeferredFinanceCostsNet
1700000
CY2023Q3 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1199500000
CY2022Q4 us-gaap Long Term Notes And Loans
LongTermNotesAndLoans
1205100000
CY2023Q3 us-gaap Long Term Debt
LongTermDebt
1219600000
CY2022Q4 us-gaap Long Term Debt
LongTermDebt
1219200000
CY2023Q3 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
121000000
CY2022Q4 us-gaap Long Term Debt And Capital Lease Obligations Current
LongTermDebtAndCapitalLeaseObligationsCurrent
18700000
CY2023Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1098600000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1200500000
CY2023Q3 us-gaap Line Of Credit Facility Maximum Borrowing Capacity
LineOfCreditFacilityMaximumBorrowingCapacity
743700000
CY2023Q3 us-gaap Letters Of Credit Outstanding Amount
LettersOfCreditOutstandingAmount
144100000
CY2023Q3 us-gaap Line Of Credit Facility Remaining Borrowing Capacity
LineOfCreditFacilityRemainingBorrowingCapacity
599600000
CY2023Q3 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
776000000
CY2022Q4 us-gaap Long Term Debt Fair Value
LongTermDebtFairValue
767800000
CY2023Q3 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1564000000
CY2023Q3 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
600000
CY2022Q4 us-gaap Derivative Notional Amount
DerivativeNotionalAmount
1412300000
CY2022Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
9600000
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
30800000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
41200000
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.258
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.319
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
80600000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
93000000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.266
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.318
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
57700000
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
54900000
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
5100000
CY2022Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
4200000
CY2023Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
200000
CY2022Q3 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
400000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
800000
us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
900000
us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.057
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
88100000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
88100000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
221700000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
199200000
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.6
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
147.8
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
146.7
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
149.1
CY2023Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.7
CY2022Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.8
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.8
us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
0.8
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.3
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
148.6
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
147.5
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
149.9
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.6
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.6
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.51
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.6
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.59
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.5
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.33
CY2022Q3 brkr Excise Tax On Stock Repurchases
ExciseTaxOnStockRepurchases
0.01
CY2023Q3 us-gaap Profit Loss
ProfitLoss
88700000
CY2022Q3 us-gaap Profit Loss
ProfitLoss
88400000
us-gaap Profit Loss
ProfitLoss
223900000
us-gaap Profit Loss
ProfitLoss
200200000
CY2023Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-52200000
CY2022Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-88300000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-16100000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-195700000
CY2023Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
21500000
CY2022Q3 us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
42900000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
-5100000
us-gaap Other Comprehensive Income Loss Derivative Excluded Component Increase Decrease After Adjustments And Tax Parent
OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAfterAdjustmentsAndTaxParent
105500000
CY2023Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
0
CY2022Q3 us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
1600000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
800000
us-gaap Other Comprehensive Income Loss Pension And Other Postretirement Benefit Plans Adjustment Net Of Tax
OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentNetOfTax
3700000
CY2023Q3 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
58000000
CY2022Q3 brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
44600000
brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
203500000
brkr Comprehensive Income Loss Net Of Tax Including Portion Attributable To Noncontrolling Interest And Redeemable Noncontrolling Interest
ComprehensiveIncomeLossNetOfTaxIncludingPortionAttributableToNoncontrollingInterestAndRedeemableNoncontrollingInterest
113700000
CY2023Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
300000
CY2022Q3 us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
-300000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
2900000
us-gaap Noncontrolling Interest In Net Income Loss Other Noncontrolling Interests Nonredeemable
NoncontrollingInterestInNetIncomeLossOtherNoncontrollingInterestsNonredeemable
-500000
CY2023Q3 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-800000
CY2022Q3 brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-600000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-1100000
brkr Comprehensive Income Loss Net Of Tax Attributable To Non Redeemable Non Controlling Interest
ComprehensiveIncomeLossNetOfTaxAttributableToNonRedeemableNonControllingInterest
-1300000
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
58500000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
45500000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
201700000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
115500000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4800000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11500000
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4800000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3900000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
13500000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
11500000
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
3900000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y8M12D
CY2023Q3 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
2200000
CY2022Q3 brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
-400000
brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
3300000
brkr Information Technology And Data Processing Cost Net
InformationTechnologyAndDataProcessingCostNet
2100000
CY2023Q3 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
3700000
CY2022Q3 brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
500000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
4300000
brkr Restructuring Charges Excluding Cost Of Sales
RestructuringChargesExcludingCostOfSales
3300000
CY2023Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1600000
CY2022Q3 us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
1700000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
7400000
us-gaap Business Combination Acquisition Related Costs
BusinessCombinationAcquisitionRelatedCosts
15100000
CY2023Q3 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1900000
CY2022Q3 brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
1200000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
5100000
brkr Other Miscellaneous Nonrecurring Expense
OtherMiscellaneousNonrecurringExpense
2500000
CY2023Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
9400000
CY2022Q3 us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
3000000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
20100000
us-gaap Other Nonrecurring Income Expense
OtherNonrecurringIncomeExpense
23000000
CY2023Q3 us-gaap Restructuring Charges
RestructuringCharges
4800000
CY2022Q3 us-gaap Restructuring Charges
RestructuringCharges
300000
us-gaap Restructuring Charges
RestructuringCharges
5700000
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
us-gaap Restructuring Charges
RestructuringCharges
4500000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1800000
us-gaap Restructuring Charges
RestructuringCharges
5700000
us-gaap Payments For Restructuring
PaymentsForRestructuring
1900000
us-gaap Restructuring Reserve Translation And Other Adjustment
RestructuringReserveTranslationAndOtherAdjustment
700000
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
4900000
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
2000000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
900000
us-gaap Investment Income Interest
InvestmentIncomeInterest
5300000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1700000
CY2023Q3 us-gaap Interest Expense
InterestExpense
3900000
CY2022Q3 us-gaap Interest Expense
InterestExpense
3700000
us-gaap Interest Expense
InterestExpense
12000000
us-gaap Interest Expense
InterestExpense
11800000
CY2023Q3 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2022Q3 us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
18300000
us-gaap Equity Method Investment Other Than Temporary Impairment
EquityMethodInvestmentOtherThanTemporaryImpairment
0
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-3300000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
1200000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-8800000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
700000
CY2023Q3 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
0
CY2022Q3 us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
300000
us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
100000
us-gaap Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component
NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
1000000
CY2023Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-100000
CY2022Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
-100000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
3800000
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
1600000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-5300000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2000000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-30100000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-8800000
brkr Cumulative Currency Translation Adjustment Loss
CumulativeCurrencyTranslationAdjustmentLoss
2700000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
124500000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
131300000
us-gaap Operating Income Loss
OperatingIncomeLoss
333400000
us-gaap Operating Income Loss
OperatingIncomeLoss
301700000
CY2023Q3 us-gaap Assets
Assets
3819600000
CY2022Q4 us-gaap Assets
Assets
3611800000

Files In Submission

Name View Source Status
brkr-20230930_cal.xml Edgar Link unprocessable
0000950170-23-062192-index-headers.html Edgar Link pending
0000950170-23-062192-index.html Edgar Link pending
0000950170-23-062192.txt Edgar Link pending
0000950170-23-062192-xbrl.zip Edgar Link pending
brkr-20230930.htm Edgar Link pending
brkr-20230930.xsd Edgar Link pending
brkr-ex31_1.htm Edgar Link pending
brkr-ex31_2.htm Edgar Link pending
brkr-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
brkr-20230930_def.xml Edgar Link unprocessable
brkr-20230930_lab.xml Edgar Link unprocessable
brkr-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
brkr-20230930_htm.xml Edgar Link completed
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending